News Vogenx surpasses expectations with $81m IPO With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.
News Hims & Hers to offer unapproved peptides to customers Telehealth firm Hims & Hers will soon start selling some unapproved peptides subject to the FDA's enforcement discretion policy announced last month.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
